What is Acalabrutinib?

Acalabrutinib is a tyrosine kinase inhibitor, suitable for patients who have received ≥1 patients with mantle cell lymphoma(MCL).

The recommended dose of acalabrutinib is 100 milligrams taken orally approximately every 12 hours, swallowed whole with water, with or without food. The most common adverse reactions of acalabrutinib (incidence≥ 30%) are :anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea and musculoskeletal pain.

Verify pregnancy status in females of reproductive potential before initiating treatment. Monitor for signs and symptoms of infection during treatment and treat promptly if infection occurs. Monitor patients for signs of bleeding and manage appropriately. Monitor complete blood count during treatment. Monitor for the development of skin cancer. Monitor for symptoms of arrhythmia and treat appropriately. Acalabrutinib is metabolized mainly by CYP3A and to a lesser extent by glutathione conjugation and amide hydrolysis. Metabolized into the main active metabolite(ACP-5862),mainly mediated byCYP3A. AcalabrutinibisCYP3A4/5, 2C8 and 2C9, does not inhibitCYPisoenzyme1A2, 2B6, 2C19 and 2D6 and are CYP Weak inducer of isoenzymes 3A4, 1A2 and 2B6. ACP-5862YesCYPIsoenzymes2C8, 2C9 and 2C19 are weak inhibitors, do not inhibitCYPisoenzymes enzymes 3A4/5, 1A2, 2B6 and 2D6 and are weak inducers of CYP3A4. Generic drugs cost about six to seven thousand per box. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.